Donepezil Market By Dosage Strength (5mg, 10mg, 23mg) , By Route of Administeration (Oral, Transdermal) By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The donepezil market was valued at $0.9 billion in 2023, and is projected to reach $1.1 billion by 2033, growing at a CAGR of 1.9% from 2024 to 2033.
Donepezil is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It belongs to a class of drugs known as acetylcholinesterase inhibitors, which work by increasing the levels of acetylcholine, a neurotransmitter involved in memory and cognitive function. Donepezil does not cure Alzheimer's, but it can help slow the progression of symptoms such as memory loss, confusion, and difficulties in thinking or reasoning, especially in the early to moderate stages of the disease.
The growth of the global donepezil market is driven by alarming rise in the prevalence of Alzheimer's and other dementias. According to a study published by the BrightFocus Foundation—a non-profit organization that funds exceptional scientific research worldwide to defeat Alzheimer’s disease, macular degeneration, and glaucoma—approximately 55 million individuals are estimated to be suffering from Alzheimer’s or other dementias. This number is anticipated to rise to 152 million by 2050. In addition, increase in awareness about Alzheimer’s disease and improved diagnostic capabilities lead to higher rates of diagnosis, contributing to the market growth. Moreover, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as people age, the brain naturally undergoes neurodegeneration, characterized by the loss of neurons and synapses, which is associated with cognitive decline and Alzheimer’s. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the introduction of generic versions of Donepezil offers more affordable treatment options, expanding the market reach and increasing patient adherence. However, common side effects of Donepezil, such as nausea, diarrhea, insomnia, and muscle cramps, can lead to treatment discontinuation or non-adherence among patients, thus impacting the market growth. In addition, the development of alternative treatments for Alzheimer's, including other medications and non-pharmacological interventions, can limit the demand for donepezil. On the contrary, ongoing research into Alzheimer's treatments and the efficacy of donepezil spurs the market interest, as new formulations or combinations with other therapies may enhance treatment outcomes. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global donepezil market is segmented into dosage strength, route of administration, distribution channel, and region. On the basis of the dosage strength, the market is categorized into 5mg, 10mg, and 23mg. By route of administration, it is classified into oral and transdermal. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By dosage strength, the 5 mg segment is expected to dominate the market from 2024 to 2033.
On the basis of route of administration, the oral segment is anticipated to exhibit the highest growth during the forecast period.
Depending on distribution channel, the drug stores & retail pharmacies segment held a substantial portion of the donepezil market share.
Region wise, North America is poised to maintain its leadership in the donepezil market in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global donepezil market include Eisai Co., Ltd. , Alteus, Corium, LLC. , DD Pharmaceuticals Pvt Ltd, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Cipla, and Alkem. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Dosage Strength
5mg
10mg
23mg
By Route Of Administeration
Oral
Transdermal
By Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Eisai Co., Ltd.
Alteus
Corium, LLC.
DD Pharmaceuticals Pvt Ltd
Intas Pharmaceuticals Ltd.
Dr. Reddy’s Laboratories Ltd.
Sun Pharmaceutical
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Cipla
Alkem
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: DONEPEZIL MARKET, BY DOSAGE STRENGTH
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Dosage Strength
- 4.2. 5mg
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. 10mg
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. 23mg
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Route Of Administeration
- 5.2. Oral
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Transdermal
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Drug Stores And Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: DONEPEZIL MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Dosage Strength
- 7.2.3. Market Size and Forecast, By Route Of Administeration
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Donepezil Market
- 7.2.6.1. Market Size and Forecast, By Dosage Strength
- 7.2.6.2. Market Size and Forecast, By Route Of Administeration
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Donepezil Market
- 7.2.7.1. Market Size and Forecast, By Dosage Strength
- 7.2.7.2. Market Size and Forecast, By Route Of Administeration
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Donepezil Market
- 7.2.8.1. Market Size and Forecast, By Dosage Strength
- 7.2.8.2. Market Size and Forecast, By Route Of Administeration
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Dosage Strength
- 7.3.3. Market Size and Forecast, By Route Of Administeration
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Donepezil Market
- 7.3.6.1. Market Size and Forecast, By Dosage Strength
- 7.3.6.2. Market Size and Forecast, By Route Of Administeration
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Donepezil Market
- 7.3.7.1. Market Size and Forecast, By Dosage Strength
- 7.3.7.2. Market Size and Forecast, By Route Of Administeration
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Donepezil Market
- 7.3.8.1. Market Size and Forecast, By Dosage Strength
- 7.3.8.2. Market Size and Forecast, By Route Of Administeration
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Donepezil Market
- 7.3.9.1. Market Size and Forecast, By Dosage Strength
- 7.3.9.2. Market Size and Forecast, By Route Of Administeration
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Donepezil Market
- 7.3.10.1. Market Size and Forecast, By Dosage Strength
- 7.3.10.2. Market Size and Forecast, By Route Of Administeration
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Donepezil Market
- 7.3.11.1. Market Size and Forecast, By Dosage Strength
- 7.3.11.2. Market Size and Forecast, By Route Of Administeration
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Dosage Strength
- 7.4.3. Market Size and Forecast, By Route Of Administeration
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Donepezil Market
- 7.4.6.1. Market Size and Forecast, By Dosage Strength
- 7.4.6.2. Market Size and Forecast, By Route Of Administeration
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Donepezil Market
- 7.4.7.1. Market Size and Forecast, By Dosage Strength
- 7.4.7.2. Market Size and Forecast, By Route Of Administeration
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Donepezil Market
- 7.4.8.1. Market Size and Forecast, By Dosage Strength
- 7.4.8.2. Market Size and Forecast, By Route Of Administeration
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. Australia Donepezil Market
- 7.4.9.1. Market Size and Forecast, By Dosage Strength
- 7.4.9.2. Market Size and Forecast, By Route Of Administeration
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Donepezil Market
- 7.4.10.1. Market Size and Forecast, By Dosage Strength
- 7.4.10.2. Market Size and Forecast, By Route Of Administeration
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Donepezil Market
- 7.4.11.1. Market Size and Forecast, By Dosage Strength
- 7.4.11.2. Market Size and Forecast, By Route Of Administeration
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Dosage Strength
- 7.5.3. Market Size and Forecast, By Route Of Administeration
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Donepezil Market
- 7.5.6.1. Market Size and Forecast, By Dosage Strength
- 7.5.6.2. Market Size and Forecast, By Route Of Administeration
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Donepezil Market
- 7.5.7.1. Market Size and Forecast, By Dosage Strength
- 7.5.7.2. Market Size and Forecast, By Route Of Administeration
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Donepezil Market
- 7.5.8.1. Market Size and Forecast, By Dosage Strength
- 7.5.8.2. Market Size and Forecast, By Route Of Administeration
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Donepezil Market
- 7.5.9.1. Market Size and Forecast, By Dosage Strength
- 7.5.9.2. Market Size and Forecast, By Route Of Administeration
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Eisai Co., Ltd.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Alteus
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Corium, LLC.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. DD Pharmaceuticals Pvt Ltd
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Intas Pharmaceuticals Ltd.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Dr. Reddy’s Laboratories Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Sun Pharmaceutical
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Cipla
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Alkem
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 2. DONEPEZIL MARKET FOR 5MG, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. DONEPEZIL MARKET FOR 10MG, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. DONEPEZIL MARKET FOR 23MG, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 6. DONEPEZIL MARKET FOR ORAL, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. DONEPEZIL MARKET FOR TRANSDERMAL, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 9. DONEPEZIL MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. DONEPEZIL MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. DONEPEZIL MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. DONEPEZIL MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. NORTH AMERICA DONEPEZIL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 16. NORTH AMERICA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 17. U.S. DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 19. U.S. DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 20. CANADA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 22. CANADA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 23. MEXICO DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 25. MEXICO DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 26. EUROPE DONEPEZIL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 29. EUROPE DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 30. GERMANY DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 31. GERMANY DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 32. GERMANY DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 33. FRANCE DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 35. FRANCE DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 36. UK DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 37. UK DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 38. UK DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 39. ITALY DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 41. ITALY DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 42. SPAIN DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 44. SPAIN DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 45. REST OF EUROPE DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 47. REST OF EUROPE DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 48. ASIA-PACIFIC DONEPEZIL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 51. ASIA-PACIFIC DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 52. JAPAN DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 53. JAPAN DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 54. JAPAN DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 55. CHINA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 57. CHINA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 58. INDIA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 59. INDIA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 60. INDIA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 61. AUSTRALIA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 62. AUSTRALIA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 63. AUSTRALIA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 64. SOUTH KOREA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 66. SOUTH KOREA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 67. REST OF ASIA-PACIFIC DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 69. REST OF ASIA-PACIFIC DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 70. LAMEA DONEPEZIL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 73. LAMEA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 74. BRAZIL DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 76. BRAZIL DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 77. SAUDI ARABIA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 78. SAUDI ARABIA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 79. SAUDI ARABIA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 80. SOUTH AFRICA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 82. SOUTH AFRICA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 83. REST OF LAMEA DONEPEZIL MARKET, BY DOSAGE STRENGTH, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA DONEPEZIL MARKET, BY ROUTE OF ADMINISTERATION, 2024 - 2033 ($BILLION)
- TABLE 85. REST OF LAMEA DONEPEZIL MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 86. EISAI CO., LTD. : KEY EXECUTIVES
- TABLE 87. EISAI CO., LTD. : COMPANY SNAPSHOT
- TABLE 88. EISAI CO., LTD. : OPERATING SEGMENTS
- TABLE 89. EISAI CO., LTD. : PRODUCT PORTFOLIO
- TABLE 90. EISAI CO., LTD. : KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 91. ALTEUS: KEY EXECUTIVES
- TABLE 92. ALTEUS: COMPANY SNAPSHOT
- TABLE 93. ALTEUS: OPERATING SEGMENTS
- TABLE 94. ALTEUS: PRODUCT PORTFOLIO
- TABLE 95. ALTEUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96. CORIUM, LLC. : KEY EXECUTIVES
- TABLE 97. CORIUM, LLC. : COMPANY SNAPSHOT
- TABLE 98. CORIUM, LLC. : OPERATING SEGMENTS
- TABLE 99. CORIUM, LLC. : PRODUCT PORTFOLIO
- TABLE 100. CORIUM, LLC. : KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101. DD PHARMACEUTICALS PVT LTD: KEY EXECUTIVES
- TABLE 102. DD PHARMACEUTICALS PVT LTD: COMPANY SNAPSHOT
- TABLE 103. DD PHARMACEUTICALS PVT LTD: OPERATING SEGMENTS
- TABLE 104. DD PHARMACEUTICALS PVT LTD: PRODUCT PORTFOLIO
- TABLE 105. DD PHARMACEUTICALS PVT LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES
- TABLE 107. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
- TABLE 108. INTAS PHARMACEUTICALS LTD.: OPERATING SEGMENTS
- TABLE 109. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
- TABLE 110. INTAS PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
- TABLE 112. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 113. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
- TABLE 114. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 115. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116. SUN PHARMACEUTICAL: KEY EXECUTIVES
- TABLE 117. SUN PHARMACEUTICAL: COMPANY SNAPSHOT
- TABLE 118. SUN PHARMACEUTICAL: OPERATING SEGMENTS
- TABLE 119. SUN PHARMACEUTICAL: PRODUCT PORTFOLIO
- TABLE 120. SUN PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: KEY EXECUTIVES
- TABLE 122. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
- TABLE 123. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: OPERATING SEGMENTS
- TABLE 124. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCT PORTFOLIO
- TABLE 125. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126. CIPLA: KEY EXECUTIVES
- TABLE 127. CIPLA: COMPANY SNAPSHOT
- TABLE 128. CIPLA: OPERATING SEGMENTS
- TABLE 129. CIPLA: PRODUCT PORTFOLIO
- TABLE 130. CIPLA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131. ALKEM: KEY EXECUTIVES
- TABLE 132. ALKEM: COMPANY SNAPSHOT
- TABLE 133. ALKEM: OPERATING SEGMENTS
- TABLE 134. ALKEM: PRODUCT PORTFOLIO
- TABLE 135. ALKEM: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL DONEPEZIL MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF DONEPEZIL MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN DONEPEZIL MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDONEPEZIL MARKET
- FIGURE 10. GLOBAL DONEPEZIL MARKET SEGMENTATION, BY DOSAGE STRENGTH
- FIGURE 11. DONEPEZIL MARKET FOR 5MG, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. DONEPEZIL MARKET FOR 10MG, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. DONEPEZIL MARKET FOR 23MG, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. GLOBAL DONEPEZIL MARKET SEGMENTATION, BY ROUTE OF ADMINISTERATION
- FIGURE 15. DONEPEZIL MARKET FOR ORAL, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. DONEPEZIL MARKET FOR TRANSDERMAL, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. GLOBAL DONEPEZIL MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 18. DONEPEZIL MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. DONEPEZIL MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. DONEPEZIL MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 25. COMPETITIVE DASHBOARD
- FIGURE 26. COMPETITIVE HEATMAP: DONEPEZIL MARKET
- FIGURE 27. TOP PLAYER POSITIONING, 2023
- FIGURE 28. EISAI CO., LTD. : NET SALES, 2021-2023 ($BILLION)
- FIGURE 29. EISAI CO., LTD. : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 30. EISAI CO., LTD. : REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 31. ALTEUS: NET SALES, 2021-2023 ($BILLION)
- FIGURE 32. ALTEUS: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 33. ALTEUS: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 34. CORIUM, LLC. : NET SALES, 2021-2023 ($BILLION)
- FIGURE 35. CORIUM, LLC. : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 36. CORIUM, LLC. : REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 37. DD PHARMACEUTICALS PVT LTD: NET SALES, 2021-2023 ($BILLION)
- FIGURE 38. DD PHARMACEUTICALS PVT LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 39. DD PHARMACEUTICALS PVT LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 40. INTAS PHARMACEUTICALS LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 41. INTAS PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 42. INTAS PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 43. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 44. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 45. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 46. SUN PHARMACEUTICAL: NET SALES, 2021-2023 ($BILLION)
- FIGURE 47. SUN PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 48. SUN PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 49. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 50. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 51. JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 52. CIPLA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 53. CIPLA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 54. CIPLA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 55. ALKEM: NET SALES, 2021-2023 ($BILLION)
- FIGURE 56. ALKEM: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 57. ALKEM: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook